🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Furoate-umeclidinium-vilanterol

Found 38 matching trials

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4

The goal of this clinical trial is to determine if triple inhaled therapy w...

Status

Completed

Location

Narongkorn Saiphoklang

Start Date

2025-04-01

Trial ID

NCT06905483

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol (BGF)Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

N/A

This study looks at data from people with chronic obstructive pulmonary dis...

Status

Completed

Location

eMax health

Start Date

2021-12-17

Trial ID

NCT05169424

Treatments Being Tested

Trelegy Ellipta Stiolto Respimat Tiotropium + Olodaterol (5/5 mcg)Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)

Replication of the IMPACT COPD Trial in Healthcare Claims Data

N/A

Investigators are building an empirical evidence base for real world data t...

Status

Completed

Location

Brigham and Women's Hospital

Start Date

2020-12-13

Trial ID

NCT05062304

Treatments Being Tested

Fluticasone Furoate-Vilanterol Trifenatate Furoate-umeclidinium-vilanterol

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

PHASE3

The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC...

Status

Completed

Location

GSK Investigational Site

Start Date

2021-07-29

Trial ID

NCT04937387

Treatments Being Tested

FF/VI FF/UMEC/VI ELLIPTA

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

PHASE4

The primary objective of this study is to evaluate the effectiveness of TRE...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-10-14

Trial ID

NCT05535972

Treatments Being Tested

FF/UMEC/VI

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

PHASE3

This is a Phase III multicenter, randomized, double-blind, double-dummy, pa...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01316900

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GW642444 tiotropium bromide

Previous Next